Title
Category
Credits
Event date
Cost
Medical Moment Two: Multifaceted Challenges in Medical Therapy Optimization during Episodes of Worsening HFrEF
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Initiating and optimizing in-hospital guideline-directed medical therapies (GDMT) remains a challenge for clinicians treating patients with worsening HFrEF. Join Drs. Muthiah Vaduganathan and Michelle Kittleson, as they discuss opportunities and strategies to employ evidence-based therapies to address these challenges.Supported through an independent educational grant from Merck.
Medical Moment Three: Multidisciplinary Collaboration  in the Management of Patients with Heart Failure
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Heart failure is a major public-health problem resulting in substantial morbidity and mortality for the US. Unfortunately, challenges and barriers to effective use of guideline-directed medical therapies (GDMT) among hospitalized patients with HFrEF remain. Join Drs. Muthiah Vaduganathan and Amulya Nagarur as they discuss practical strategies and insights into using GDMT, and opportunities for multidisciplinary partnerships when treating these patients.
Medical Moment One: Novel Pharmacologic Approaches in a Symptomatic, High-risk HFrEF Patient Population
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Join Drs. Muthiah Vaduganathan and Javed Butler for this on-demand online activity, as they examine novel methodologies to address the clinical worsening of HFrEF, with a focus on recently-reported results from the VICTORIA trial.Supported through an independent educational grant from Merck.
Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface
  • Cardiology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies. The vicious cycle of cardiorenal anemia syndrome (CRAS)—the pathologic triad wherein the three conditions are each capable of causing and/or being caused by the other—can be effectively mitigated and managed with IV iron.
Interprofessional Perspectives on the Evolving Heart Failure Treatment Paradigm: Harnessing Novel Therapeutics to Optimize Outcomes & Overcome Disparities in Care
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
$0.00
Please Note: Credit Is No Longer Available Listen on CEConversations
IV Iron Expert Exchange: Data-driven Debates on the Revolutionary Role of IV Iron in Heart Failure
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
11/05/2022
$0.00
To register in advance click here: https://us06web.zoom.us/webinar/register/WN_lNOW5KvGQcy37LkauNu7fg